Cereno Scientific moves to new office space at GoCo Health Innovation City in Gothenburg

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that the Company is moving to a new office space at GoCo Health Innovation City in Gothenburg in June 2024. The re-location to GoCo’s inspiring community will support the further propelling of Cereno’s pipeline and the next step of the Company’s growth journey.

Cereno Scientific’s pipeline comprises late-stage Phase II drug candidate CS1, an HDAC inhibitor with epigenetic effects for the treatment of the rare disease Pulmonary Arterial Hypertension (PAH) with the aim of offering patients an effective, safe and disease-modifying drug; CS014, an HDAC inhibitor with epigenetic effects, being developed for thrombosis prevention, with a first-in-human Phase I study planned to start in Q2 2024; and CS585, a novel IP receptor agonist. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Pulmonary Hypertension and thrombosis prevention without increased risk of bleeding. Cereno Scientific has reported positive findings over the last months, suggesting potential clinical benefit of CS1 in patients. Study completion and topline results are expected during Q3 2024. On January 30, Cereno was granted approval by the FDA for Expanded Access for CS1 to use in an extension of the ongoing Phase II trial evaluating CS1 in PAH.

After eight fruitful years at AstraZeneca’s BioVentureHub, Cereno Scientific has chosen to re-locate to GoCo Health Innovation City, to facilitate the next level of growth and development. GoCo Health Innovation City hosts a diverse set of companies, organizations, and individuals working to unlock new solutions to global health challenges. Here is a world-class innovation cluster for health being created, with collaboration built into the core.

“Cereno was founded in 2012, with support from GU Ventures. During the last years at BioVentureHub, Cereno has matured from a young biotech, listed on the Spotlight Stock Market in 2016, to a growing billion SEK company with a late Phase II candidate. We uplisted to Nasdaq First North Growth Market in 2023, raised over 500 MSEK in capital and engaged in joint ventures with other BioVentureHub companies, including the CS014 project with Emeriti Bio that is now progressing into the clinic after the submission of a CTA for a first-in-human Phase I Study. The re-location to our new office space at GoCo Health Innovation City is a natural next step for Cereno, and it will allow us to continue our growth journey. We look forward to working in this inspiring environment with other fast-growing Life Science companies”, said Sten R. Sörensen, CEO, Cereno Scientific."

“At GoCo Health Innovation City, we're excited to see our collaborative ecosystem foster growth and innovation. Cereno Scientific's expansion from the BioVentureHub to a larger space at GoCo showcases the success of this, along with our strong partnership with AstraZeneca. We're truly inspired by Cereno Scientific's progress and eagerly look forward to their continued growth within our facilities and community," shared Marie Uddenmyr, Director of Corporate Relations at GoCo Health Innovation City.

“BioVentureHub gives emerging life science companies and academic groups a unique opportunity to co-locate with and tap into the power of AstraZeneca’s world-class scientists and state of the art lab facilities and infrastructure, and with each other. We are happy to have had Cereno Scientific with us for such a long time. Cereno has matured well as a company during their time with us, and they are a great example of our vision in practice: to cultivate the premier ecosystem for life science innovation, where a robust culture of creativity and collaboration accelerates the convergence of data, science, and technology resulting in sustainable healthcare solutions”, said Magnus Björsne, CEO, BioVentureHub.

For further information, please contact:

Henrik Westdahl, Director IR & Communications

Email: henrik.westdahl@cerenoscientific.com

Phone: +46 70-817 59 96

Sten R. Sörensen, CEO

Email: sten.sorensen@cerenoscientific.com

Phone: +46 73-374 03 74

About Cereno Scientific AB

Cereno Scientific develops innovative treatments for common and rare cardiovascular disease. The lead drug candidate, CS1, is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Two initiatives performed during the ongoing Phase II study have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final study results that are expected in Q3 2024. Since January 2024, we are delighted that the FDA´s Expanded Access Program will enable patients with PAH, a serious life-threatening disease condition, to gain access to CS1 where no comparable alternative therapy options are available. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Investigational drug CS014 is an HDAC inhibitor in development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment potentially without the associated increased risk of bleeding in humans. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding as documented in preclinical studies. In April 2024, Cereno submitted a Clinical Trial Application (CTA) for a Phase I First-in-Human-Study, expected to start during Q2 2024. Drug candidate CS585 is a prostacyclin receptor agonist. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Pulmonary Hypertension and thrombosis prevention without increased risk of bleeding. CS585 was in-licensed from the University of Michigan in 2023. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.